| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11253474 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | |
| US11458095 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | |
| US11723866 | CMP DEV LLC | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | |
Norliqva is owned by Cmp Dev Llc.
Norliqva contains Amlodipine Besylate.
Norliqva has a total of 3 drug patents out of which 0 drug patents have expired.
Norliqva was authorised for market use on 24 February, 2022.
Norliqva is available in solution;oral dosage forms.
Norliqva can be used as norliqva is indicated for the symptomatic treatment of chronic stable angina, norliqva is indicated for the treatment of confirmed or suspected vasospastic angina.
The generics of Norliqva are possible to be released after 24 February, 2041.
Drugs and Companies using AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 24 February, 2022
Treatment: Norliqva is indicated for the treatment of confirmed or suspected vasospastic angina; Norliqva is indicated for the symptomatic treatment of chronic stable angina
Dosage: SOLUTION;ORAL
NORLIQVA family patents
